Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Braskem is considering expanding its ethylene cracker and polyethylene complex in the Brazilian state of Rio de Janeiro by 220,000 metric tons per year. During a call with analysts, company officials ...

Blood and urine tests might be able to reveal how much of your diet is made up of industrially produced foods, a new study ...

The story of chronic itch and its impact on quality of life is one dermatologists have heard often. Until recently, treatment ...

We have highlighted five single-stock ETFs that have doubled over the past month amid a historic Wall Street comeback.

The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 151.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

About a fourth of younger men surveyed in the United States feel lonely, which is significantly higher than the national ...

CALIFORNIA, CA, UNITED STATES, May 20, 2025 /EINPresswire.com/ -- The Type 2 Diabetes market is undergoing significant ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...